Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Stifel Analyst Reaffirms Buy Rating for Equinix with 960 Price Target

Elaine Mendonca by Elaine Mendonca
March 13, 2024
in Breaking News
0
Finance_ Charts for stock trading
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

Stifel analyst Erik Rasmussen has once again expressed his confidence in Equinix (NASDAQ: EQIX), giving it a Buy rating and sticking to a $960 price target. __________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

EQIX Stock Price Analysis: March 13, 2024 – Potential Investment Opportunity

On March 13, 2024, EQIX stock experienced a slight decrease in its price momentum. The stock opened at $883.51, which was $9.30 lower than its previous close. Throughout the day, the price of EQIX shares dropped by $21.37, representing a 2.39% decrease from the previous market close.

Despite the decrease in price on this particular day, EQIX has been performing well overall, trading near the top of its 52-week range. Additionally, being above its 200-day simple moving average suggests that the stock has been trending upwards over the past few months.

Investors may want to keep an eye on EQIX stock to see if the price momentum continues in the coming days. It is always important to conduct thorough research and analysis before making any investment decisions. Consulting with a financial advisor or conducting your own research on the company’s financials, industry trends, and market outlook can help you make informed decisions about investing in EQIX or any other stock.

EQIX Stock Shows Strong Financial Performance in 2024: A Favorable Investment Option for Investors

On March 13, 2024, EQIX stock showed strong financial performance based on the data provided by CNN Money. The company’s total revenue for the past year was $8.19 billion, with a significant increase of 12.71% compared to the previous year. Net income for EQIX was $969.18 million for the past year, marking a notable increase of 37.6% since the previous year. Earnings per share (EPS) for EQIX stood at $10.31 for the past year, showing a substantial increase of 34.41% compared to the previous year. Overall, EQIX demonstrated strong financial performance with increases in total revenue, net income, and EPS compared to the previous year. Investors may view EQIX stock as a favorable investment option based on its solid financial performance and potential for growth. However, it is essential for investors to conduct thorough research and analysis before making any investment decisions.

Tags: EQIX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Bellevue dues

Analysts Remain Bullish on Alcon with Buy Ratings and Price Target Increases

why did walmart get rid of price scanners

Truist Securities Analyst Reaffirms Positive Outlook on Keros Therapeutics with 100 Price Target

Club membership cost

Flotek Industries Sees Surge in Stock Prices Following Q4 Financial Report

Recommended

EEFT stock news

Analyst Ratings and Price Targets for Definitive Healthcare

2 years ago
Healthcare Services Stock Exchange

Analyst Ratings and Price Targets for Inari Medical NASDAQNARI

2 years ago
STZ stock news

Analyzing Analyst Recommendations and Target Price for FirstEnergy Corp.

2 years ago
Healthcare-sector

Introducing the Revolutionary Herbalife GLP1 Nutrition Companion

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Molina Healthcare: Crisis or Opportunity as Legal Storms and a Legendary Investor Collide?

Nio’s Unprecedented Delivery Streak Fuels Profitability Push

Is 3M’s Resurgence Signaling a Sustainable Recovery?

Eastman Chemical’s Challenging Quarter: A Deep Dive into the Numbers

BioNTech’s Crossroads: Navigating Losses Amid Cancer Research Promise

China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally

Trending

MannKind Stock
Analysis

MannKind Shares Surge on Exceptional Quarterly Performance

by Robert Sasse
November 6, 2025
0

MannKind Corporation witnessed a substantial rally in its share price following the release of its third-quarter 2025...

Amgen Stock

Amgen’s Impressive Quarterly Performance Fuels Investor Confidence

November 6, 2025
Teledyne Stock

An Overlooked AI Contender Emerges in Defense Technology

November 6, 2025
Molina Healthcare Stock

Molina Healthcare: Crisis or Opportunity as Legal Storms and a Legendary Investor Collide?

November 6, 2025
Nio Stock

Nio’s Unprecedented Delivery Streak Fuels Profitability Push

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • MannKind Shares Surge on Exceptional Quarterly Performance
  • Amgen’s Impressive Quarterly Performance Fuels Investor Confidence
  • An Overlooked AI Contender Emerges in Defense Technology

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com